Neonatal jaundice nursing: assessment, phototherapy, and NCLEX tips

Neonatal jaundice — yellowing of the skin and sclera caused by elevated bilirubin — affects up to 60% of term newborns and 80% of preterm infants in the first week of life. For most, it is a transient, physiologic process that resolves without treatment. For a subset, unchecked hyperbilirubinemia can cross the blood-brain barrier and cause acute bilirubin encephalopathy, with permanent neurological injury if severe. The nursing role is to identify which newborns fall into that high-risk subset, interpret bilirubin values correctly, apply phototherapy safely, monitor for signs of escalation, and educate families — all within the compressed timeline of a 48-hour postpartum stay.

This reference covers the full clinical picture: pathophysiology, risk stratification, the Bhutani nomogram, phototherapy management, exchange transfusion thresholds, kernicterus, breastfeeding jaundice, and 10 NCLEX tips. Read it alongside the neonatal nursing reference, neonatal hypoglycemia nursing, and neonatal resuscitation nursing for a comprehensive neonatal cluster.

Quick reference: neonatal jaundice at a glance

Pathophysiology

Bilirubin is a byproduct of heme catabolism. When red blood cells are broken down, the heme ring is cleaved, producing unconjugated (indirect) bilirubin. This form is lipid soluble and tightly bound to albumin in the bloodstream, which normally prevents it from entering the brain. In the liver, unconjugated bilirubin is taken up by hepatocytes, where the enzyme UDP-glucuronosyltransferase (UGT1A1) conjugates it with glucuronic acid to form water-soluble direct bilirubin — which is then excreted via bile into the gut.

Newborns are predisposed to hyperbilirubinemia for several overlapping reasons. First, fetal hemoglobin (HbF) has a shorter lifespan than adult hemoglobin — the rapid turnover of fetal RBCs after birth creates a surge in bilirubin production. Second, neonatal hepatic UGT1A1 activity is immature, limiting conjugation capacity. Third, the newborn gut is sterile at birth — the bacteria that normally convert bilirubin to urobilinogen are absent, so intestinal beta-glucuronidase deconjugates bilirubin back to the unconjugated form, which is then reabsorbed. This enterohepatic recirculation significantly amplifies bilirubin load.

Physiologic vs pathologic jaundice is distinguished primarily by timing and rate of rise. Physiologic jaundice appears on day 2–3 of life, peaks around day 3–4 in term infants (day 5–7 in preterm), and resolves by day 10–14. Any jaundice appearing in the first 24 hours of life is pathologic by definition and demands immediate evaluation — it implies a process producing bilirubin faster than the liver can handle, most commonly hemolysis.

Kernicterus mechanism. When serum bilirubin rises sharply, or when albumin binding capacity is overwhelmed (by acidosis, hypoxia, hypoalbuminemia, or displacement by drugs), free unconjugated bilirubin crosses the blood-brain barrier. It is selectively deposited in the basal ganglia, hippocampus, cranial nerve nuclei, and cerebellum, triggering neuronal death. Acute bilirubin encephalopathy (BIND) is the reversible early phase; kernicterus is the irreversible chronic sequel.

Risk factors for significant hyperbilirubinemia

Risk stratification is critical. The same TSB value carries different clinical weight depending on gestational age, age in hours, and the presence of neurotoxicity risk factors — a principle formalized in the 2022 AAP guidelines (Kemper et al., Pediatrics 2022).

Assessment and diagnosis

Screening vs confirmation

TcB (transcutaneous bilirubin) is measured non-invasively using a reflectance-based meter placed on the forehead or sternum. It correlates reasonably well with TSB in the normal range but becomes less reliable at high bilirubin concentrations, after phototherapy has started (phototherapy bleaches skin), in dark-pigmented skin, or in preterm infants. TcB is a screening tool only — it cannot be used to make treatment decisions. When TcB approaches or exceeds a threshold, a confirmatory TSB (serum sample) is required.

TSB (total serum bilirubin) requires a blood draw (heel stick or venipuncture) and is reported as total bilirubin plus a fractionated value (conjugated + unconjugated). TSB is the basis for all phototherapy and exchange transfusion decisions. Always document the age in hours when the sample is drawn — the Bhutani nomogram requires this.

The Bhutani nomogram

The Bhutani nomogram (Bhutani et al., Pediatrics 1999; incorporated into AAP 2004 and 2022 guidelines) plots TSB against postnatal age in hours for infants ≥35 weeks. It divides risk into four zones:

• Low risk zone (below 40th percentile): routine discharge, standard follow-up
• Low-intermediate risk zone (40th–75th percentile): follow-up within 2–3 days
• High-intermediate risk zone (75th–95th percentile): follow-up within 24 hours, consider phototherapy
• High risk zone (above 95th percentile): high probability of significant hyperbilirubinemia; same-day phototherapy evaluation

The critical nursing implication: a TSB of 12 mg/dL at 24 hours of age is in the high-risk zone and demands immediate action. The same 12 mg/dL at 96 hours may fall in the low-intermediate zone. The value only makes sense in context of age in hours — always record both together.

Additional diagnostic testing

The direct antiglobulin test (DAT or Coombs test) detects maternal antibodies bound to fetal RBCs. A positive DAT confirms immune-mediated hemolysis (ABO or Rh incompatibility) and changes management: these infants are at higher risk for rapid bilirubin escalation and may need earlier phototherapy and closer monitoring. DAT is indicated when jaundice appears in the first 24 hours, when TSB is rising rapidly, or when the mother is type O or Rh-negative.

A blood type and screen on cord blood is recommended for all infants born to type O or Rh-negative mothers by AAP 2022 guidelines.

G6PD enzyme assay should be ordered when there is a family history of G6PD deficiency, the infant is of relevant ancestry, or jaundice is unexpectedly severe or refractory to phototherapy.

Physical assessment findings

Jaundice progresses in a predictable cephalocaudal pattern — the Kramer zones:

• Zone 1 (face/head): TSB ~5–7 mg/dL
• Zone 2 (trunk to umbilicus): TSB ~8–10 mg/dL
• Zone 3 (abdomen below umbilicus): TSB ~11–13 mg/dL
• Zone 4 (knees/elbows to wrists/ankles): TSB ~13–15 mg/dL
• Zone 5 (hands and feet): TSB >15 mg/dL

Clinical assessment of jaundice by skin zone is useful as a rough screen but is unreliable for treatment decisions — skin color is affected by pigmentation, lighting, and observer experience. TSB must be measured; never rely on visual assessment alone to decide whether to treat.

Neurological warning signs that indicate bilirubin neurotoxicity (BIND) require immediate escalation: high-pitched cry, poor feeding, excessive sleepiness, decreased tone, retrocollis (backward neck arching), opisthotonus, and in severe cases, seizures.

Treatment and nursing management

Phototherapy

Phototherapy is the primary treatment for unconjugated hyperbilirubinemia. Blue-spectrum light (wavelength ~460–490 nm) converts unconjugated bilirubin in the skin and superficial capillaries into photoisomers — primarily lumirubin — that are water soluble and can be excreted in bile and urine without hepatic conjugation.

Standard vs intensive phototherapy differs by irradiance. Intensive phototherapy requires spectral irradiance ≥30 μW/cm²/nm at the infant’s skin surface, achieved by using a higher-power light source, reducing the distance between lamp and infant, or placing a bili-blanket beneath the infant simultaneously (double phototherapy). Intensive phototherapy is used when TSB is within 2–3 mg/dL of the exchange transfusion threshold, or when TSB is rising rapidly.

2022 AAP guideline change. The updated Kemper et al. (Pediatrics 2022) guidelines replaced the prior single-threshold nomogram with risk-stratified thresholds that account for gestational age (in weeks) AND the presence of neurotoxicity risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, sepsis, acidosis, albumin <3.0 g/dL, East Asian ancestry). An infant with neurotoxicity risk factors requires phototherapy at lower TSB values than a neurologically intact term infant. This represents a significant clinical shift from older guidelines.

Nursing management during phototherapy:

• Eye shields are mandatory throughout phototherapy — blue-spectrum light causes retinal damage. Remove only during feeding and parental bonding.
• Maximize skin exposure. Undress the infant to a diaper only. Remove the diaper only during intensive phototherapy when increasing exposed surface area is critical, and only with physician order.
• Hydration monitoring. Phototherapy increases insensible water loss through the skin and respiratory tract. Monitor weight, urine output (at least 6 wet diapers/day once feeding is established), urine specific gravity, and skin turgor. Increase feeding frequency. IV fluids are rarely needed unless the infant is unable to feed adequately.
• Temperature regulation. Phototherapy lights generate heat. Monitor temperature q2–4h to prevent hyperthermia. Incubator temperature may need adjustment.
• Position changes. Rotate position (supine, prone, side) to maximize skin surface exposure and prevent pressure injuries. Document positioning with each TSB check.
• TSB monitoring frequency. Per AAP 2022: monitor TSB every 4–6 hours when TSB is rising rapidly or near exchange threshold; every 8–12 hours once TSB is stable and declining.
• Parental education. Explain the purpose of phototherapy, why eye shields are used, that the infant will be in the light as much as possible, and that breastfeeding continues (remove from phototherapy for feeds). Reassure that jaundice visible in UV light does not indicate internal bleeding.

Exchange transfusion

Exchange transfusion is reserved for severe hyperbilirubinemia that does not respond to intensive phototherapy, or when there are clinical signs of acute bilirubin encephalopathy. It is a procedure with significant risk and is performed only in NICUs with appropriate expertise.

Indications (AAP 2022):

• TSB at or above the exchange transfusion threshold on the risk-stratified nomogram
• Any clinical signs of acute bilirubin encephalopathy (regardless of TSB level)
• TSB rising despite intensive phototherapy at a rate suggesting it will reach the exchange threshold

Procedure. A double-volume exchange (approximately 160–170 mL/kg — calculated as 85 mL/kg × 2) is performed via umbilical venous catheter. Donor blood (typically irradiated, CMV-negative packed RBCs reconstituted with fresh frozen plasma to a hematocrit of ~50%) is incrementally exchanged with the infant’s blood in aliquots of 5–20 mL, removing bilirubin-loaded RBCs and replacing them with donor cells not coated in maternal antibodies. This reduces TSB by approximately 50% immediately, though rebound can occur as extravascular bilirubin redistributes.

Nursing role during exchange transfusion: continuous cardiorespiratory monitoring (heart rate, SpO₂, blood pressure), strict intake/output documentation of each aliquot exchanged, temperature maintenance, blood product verification (two-nurse identification), and monitoring for complications — hypocalcemia (citrate in donor blood chelates calcium; calcium gluconate available), bradycardia, necrotizing enterocolitis, thrombocytopenia, and air embolism.

Complications: kernicterus and BIND

Acute bilirubin encephalopathy (BIND) is the spectrum of neurological injury caused by bilirubin neurotoxicity, progressing through three phases:

1. Early/phase 1 (potentially reversible): subtle lethargy, decreased tone, poor feeding, high-pitched cry. Often mistaken for normal newborn sleepiness — this is the window for intervention.
2. Intermediate/phase 2: worsening lethargy and hypotonia alternating with irritability and hypertonia; retrocollis (neck extension); fever. Partially reversible with exchange transfusion.
3. Advanced/phase 3: pronounced retrocollis, opisthotonus (full body arching), shrill cry, apnea, seizures, coma. Largely irreversible.

Kernicterus is the chronic, permanent neurological sequela — the endpoint of severe, untreated BIND. The classic tetrad includes:

• Choreoathetoid cerebral palsy (involuntary writhing movements)
• Sensorineural hearing loss (audiologic brainstem damage)
• Gaze palsy (inability to look upward — “sunset sign” of upward gaze restriction)
• Intellectual disability (variable)

The vulnerability of the blood-brain barrier to bilirubin is amplified by prematurity, acidosis, hypoxia, hypoalbuminemia, hypothermia, and sepsis — all of which reduce albumin binding capacity or compromise barrier integrity.

The BIND score (Johnson & Bhutani, Semin Perinatol 2011) is a clinical tool for staging acute bilirubin encephalopathy: scoring mental status (normal/sleepy vs abnormal), muscle tone (normal vs abnormal), and cry (normal vs high-pitched), with scores 0–9. A score ≥3 indicates moderate/severe BIND requiring emergency escalation.

Breastfeeding jaundice vs breastmilk jaundice

These two conditions are frequently confused on NCLEX and in clinical practice. They are distinct entities with different timing, mechanisms, and management.

Breastfeeding jaundice (early onset, days 1–4) occurs when caloric intake and fluid volume are insufficient — typically in the setting of poor latch, infrequent feeds, or delayed milk coming in. Inadequate caloric intake slows gut motility and increases enterohepatic recirculation of bilirubin. The infant may also be mildly dehydrated, concentrating the bilirubin load. Management focuses on improving breastfeeding: increasing feed frequency to 8–12 times per day, lactation consultation, and monitoring weight closely. Supplementation with formula may be appropriate when weight loss exceeds 10% or TSB is at threshold. Temporary interruption of breastfeeding is not indicated.

Breastmilk jaundice (late onset, days 3–5, peaks at week 2) is a distinct syndrome in otherwise healthy, well-fed breastfed infants. It is thought to result from a factor in mature breast milk — possibly an inhibitor of UDP-glucuronosyltransferase (UGT1A1) activity, potentially pregnanediol or nonesterified fatty acids — that reduces hepatic conjugation capacity. The infant feeds well, gains weight normally, and shows no other signs of illness. TSB is elevated but usually resolves by 3–6 weeks without intervention. If the diagnosis is uncertain, temporary discontinuation of breastfeeding for 24–48 hours produces a measurable TSB drop, confirming the diagnosis — after which breastfeeding resumes. Permanent discontinuation is never recommended for breastmilk jaundice.

The key distinction for clinical decision-making: breastfeeding jaundice requires improving feeding; breastmilk jaundice requires reassurance and continued monitoring, with temporary interruption only for diagnostic confirmation when TSB is concerning.

NCLEX tips

• Physiologic jaundice never appears in the first 24 hours. Any jaundice visible before 24 hours of life is pathologic and requires immediate evaluation — suspect hemolysis (ABO incompatibility, Rh incompatibility, G6PD deficiency).

• Jaundice progresses face → trunk → extremities (Kramer zones). Hands and feet turning yellow suggests a high TSB (>15 mg/dL). Clinical inspection is a screening cue only — TSB must be confirmed via blood sample for treatment decisions.

• TcB is for screening; TSB is for treatment decisions. Questions that ask whether to initiate phototherapy based on a TcB reading are traps — a confirmatory TSB is required before treating.

• Eye shields are mandatory during phototherapy. Blue-spectrum light (460–490 nm) causes retinal damage. Remove only for feeding and bonding. If asked the priority nursing intervention for phototherapy, eye protection comes first.

• Phototherapy increases insensible water loss. Increase breastfeeding/formula frequency during phototherapy. Monitor weight, urine output (≥6 wet diapers/day when feeding is established), and signs of dehydration.

• The Coombs test (direct antiglobulin test) detects maternal antibodies (anti-A, anti-B, anti-D) attached to fetal red blood cells. A positive result confirms immune-mediated hemolysis. Order when jaundice appears <24h, when TSB rises rapidly, or when mother is type O or Rh-negative.

• Kernicterus warning signs: high-pitched cry, opisthotonus, seizures. Retrocollis (neck arching back) and opisthotonus (full body arching) are late findings — by this stage, damage is largely irreversible. High-pitched cry and poor feeding are earlier, actionable signs.

• Breastfeeding jaundice (early onset) vs breastmilk jaundice (late onset, day 3–5): breastfeeding jaundice — increase feeds; breastmilk jaundice — continue breastfeeding, reassure, temporary interruption only if diagnostic confirmation is needed.

• Exchange transfusion is a double-volume exchange: approximately 85 mL/kg × 2 = ~170 mL/kg via umbilical venous catheter. Removes bilirubin-coated RBCs and replaces them with donor cells, reducing TSB by ~50% acutely.

• Conjugated (direct) hyperbilirubinemia is always pathological. A conjugated fraction >1 mg/dL or >20% of TSB is never normal — it indicates hepatobiliary pathology (biliary atresia, neonatal hepatitis, TORCH infections) and requires urgent evaluation regardless of total TSB level.

Sources and clinical references

Clinical content in this article is based on the following authoritative sources:

• Kemper AR, Newman TB, Slaughter JL, et al. “Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.” Pediatrics. 2022;150(3):e2022058859. (2022 AAP guideline — current standard.)
• Bhutani VK, Johnson L, Sivieri EM. “Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns.” Pediatrics. 1999;103(1):6–14. (Bhutani nomogram.)
• Johnson LH, Bhutani VK. “The clinical syndrome of bilirubin-induced neurologic dysfunction.” Semin Perinatol. 2011;35(3):101–113. (BIND staging and BIND score.)
• American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. “Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.” Pediatrics. 2004;114(1):297–316. (2004 AAP guideline — Bhutani nomogram integration.)
• Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. “Hyperbilirubinemia in the newborn infant ≥35 weeks’ gestation: an update with clarifications.” Pediatrics. 2009;124(4):1193–1198.
• Kenner C, Lott JW. Comprehensive Neonatal Nursing Care. 6th ed. Springer; 2020. (Nursing practice reference.)

For broader neonatal nursing context, see the neonatal nursing reference. For NRP and delivery room management, see neonatal resuscitation nursing. For concurrent metabolic concerns in at-risk newborns, see neonatal hypoglycemia nursing. For lab value interpretation in context, see the nursing lab values cheat sheet. For the OB cluster, see postpartum hemorrhage nursing and preterm labor nursing.